Metabolic dysfunction associated steatohepatitis (MASH)
Clinical trials for Metabolic dysfunction associated steatohepatitis (MASH) explained in plain language.
Never miss a new study
Get alerted when new Metabolic dysfunction associated steatohepatitis (MASH) trials appear
Sign up with your email to follow new studies for Metabolic dysfunction associated steatohepatitis (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets fatty liver in genetically At-Risk patients
Disease control CompletedThis early-stage trial tested a new drug, LY3849891, in 115 people with fatty liver disease who carry a specific gene variant (PNPLA3 I148M). The main goal was to check safety and how the body processes the drug. Researchers also looked at changes in liver fat and inflammation us…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New infusion drug targets MASH cirrhosis in small safety trial
Disease control CompletedThis study tested a drug called BI 770371 in 28 people with compensated cirrhosis caused by MASH, a liver disease linked to metabolism. Participants received either the drug or a placebo as an infusion every 3 weeks for 12 weeks. The main goal was to see how well the drug is tole…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Healthy volunteers test new MASH drug in early safety trial
Knowledge-focused CompletedThis early-stage study tests the safety and tolerability of a new drug called QL2401 in 70 healthy Chinese adults aged 18 to 45. Participants receive either the drug or a placebo to see how the body handles it. The goal is to gather initial safety data before testing in people wi…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
MASH awareness survey completed: no treatment, just insights
Knowledge-focused CompletedThis study used online questionnaires to understand how well healthcare providers and people with or at risk for MASH (a liver disease) understand the links between MASH and heart, kidney, and metabolic conditions. About 1,330 participants completed the 25-minute survey. The goal…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC